Cetera Investment Advisers
BCRX icon

Cetera Investment Advisers’s BioCryst Pharmaceuticals BCRX Stock Holding History

Cetera Investment Advisers’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.07M Buy
107,162
+58,749
+121% +$531K ﹤0.01% 3001
2026
Q1 		$461K Buy
48,413
+36,083
+293% +$280K ﹤0.01% 3586
2025
Q4 		$96.2K Buy
12,330
+1,494
+14% +$10.8K ﹤0.01% 4410
2025
Q3 		$82.2K Buy
+10,836
New +$90.2K ﹤0.01% 4365

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Cetera Investment Advisers's BCRX Position: Q2 2026 in Review

Cetera Investment Advisers increased its BioCryst Pharmaceuticals (BCRX) stake by 121% in Q2 2026, buying an estimated $531K and bringing the position to 107,162 shares worth $1.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3001.

Cetera Investment Advisers first reported a position in BCRX in Q3 2025 and has held it in 4 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

  • Cetera Investment Advisers held 107,162 shares of BioCryst Pharmaceuticals worth $1.07M as of Q2 2026.
  • Cetera Investment Advisers bought 58,749 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $531K.
  • BioCryst Pharmaceuticals made up ﹤0.01% of Cetera Investment Advisers's portfolio in Q2 2026, its #3001 holding.
  • Cetera Investment Advisers first reported a position in BioCryst Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.